Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.
Barnabas GD, Bhat TA, Goebeler V, Leclair P, Azzam N, Melong N, Anderson C, Gom A, An S, Ergin EK, Shen Y, Conrrero A, Mungall AJ, Mungall KL, Maxwell CA, Reid GSD, Hirst M, Jones S, Chan JA, Senger DL, Berman JN, Parker SJ, Bush JW, Strahlendorf C, Deyell RJ, Lim CJ, Lange PF.
Barnabas GD, et al. Among authors: parker sj.
EMBO Mol Med. 2025 Apr;17(4):625-644. doi: 10.1038/s44321-025-00212-8. Epub 2025 Apr 1.
EMBO Mol Med. 2025.
PMID: 40204966
Free PMC article.